Ghassan Abou-Alfa, MD, Robert Lewandowski, MD, FSIR, and Amit Singal, MD discuss potential novel combination therapies including immune checkpoint inhibitors plus tyrosine kinase inhibitors plus local-regional therapeutic strategies.
FAK Inhibition Emerges as a Potential Complementary Treatment Pathway
D'Amato Discusses Research and Resistance Mechanisms in Sarcoma and Gastrointestinal Stromal Tumor
Durvalumab Plus Chemo Sustains 3-Year OS Benefit in Advanced Biliary Tract Cancer
Acuna Discusses US Liver Cancer Incidence in Individuals of Mexican Descent
Insider Insights: Unveiling Takeaways from AACR 2024
CAN-2409 Receives FDA Orphan Drug Designation in Pancreatic Cancer
Navigating the Intersection of Radiation Therapy and Immunotherapy in Endometrial Cancer
As Orthopedic Oncology Evolves, Caring for the Clinician Must Be a Priority
Belumosudil Produces Long-Term Responses Without New Safety Concerns in cGVHD
Prophylactic Itacitinib May Safely Mitigate CRS Following Axi-Cel Administration in Lymphoma